IDH1 mutation

News alerts, weekly reports and conference planners

Entrez ID:

3417

Related biomarkers:

Expression

Mutation

Others

‹

›

IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval SOHO 2022 - 1 week (New C3) ivosidenib Sensitive : A1 SOHO 2022 - 1wk	ivosidenib Sensitive: A1 - Approval SOHO 2022 - 1 week ivosidenib Sensitive : A1 SOHO 2022 - 1 week - (New C3)
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	venetoclax + ivosidenib Sensitive: C3 – Early Trials SOHO 2022 - 1 week (New C3) venetoclax + ivosidenib Sensitive : C3 SOHO 2022 - 1wk	venetoclax + ivosidenib Sensitive: C3 – Early Trials SOHO 2022 - 1 week venetoclax + ivosidenib Sensitive : C3 SOHO 2022 - 1 week - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C3 – Early Trials SOHO 2022 - 1 week (New C3) MEN1703 Sensitive : C3 SOHO 2022 - 1wk	MEN1703 Sensitive: C3 – Early Trials SOHO 2022 - 1 week MEN1703 Sensitive : C3 SOHO 2022 - 1 week - (New C3)
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval Target Oncol - 2 weeks (New C4) ivosidenib Sensitive : A1 Target Oncol - 2wk	ivosidenib Sensitive: A1 - Approval Target Oncol - 2 weeks ivosidenib Sensitive : A1 Target Oncol - 2 weeks - (New C4)
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH1 mutation	Sarcoma	IDH1 mutation	Sarcoma	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2	ivosidenib Sensitive: A2 - Guideline ivosidenib Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	PCV Sensitive: B - Late Trials PCV Sensitive : B	PCV Sensitive: B - Late Trials PCV Sensitive : B
IDH1 mutation	Glioma	IDH1 mutation	Glioma	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1	ivosidenib Sensitive: C1 - Off-label ivosidenib Sensitive : C1
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2	temozolomide Sensitive: C2 – Inclusion Criteria temozolomide Sensitive : C2
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	S095032 Sensitive: C2 – Inclusion Criteria S095032 Sensitive : C2	S095032 Sensitive: C2 – Inclusion Criteria S095032 Sensitive : C2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3	venetoclax + ivosidenib Sensitive: C3 – Early Trials venetoclax + ivosidenib Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	FT-2102 Sensitive: C3 – Early Trials FT-2102 Sensitive : C3	FT-2102 Sensitive: C3 – Early Trials FT-2102 Sensitive : C3
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3	venetoclax + sorafenib Resistant: C3 – Early Trials venetoclax + sorafenib Resistant : C3
IDH1 mutation	Chronic Myelomonocytic Leukemia	IDH1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IDH1 mutation	Glioma	IDH1 mutation	Glioma	BAY1436032 Sensitive: C3 – Early Trials BAY1436032 Sensitive : C3	BAY1436032 Sensitive: C3 – Early Trials BAY1436032 Sensitive : C3
IDH1 mutation	Anaplastic Astrocytoma	IDH1 mutation	Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials PCV Sensitive : C3	PCV Sensitive: C3 – Early Trials PCV Sensitive : C3

IDH1 mutation

Associations